NTPC to take over Kanti, Nabinagar JV plants for Rs3,000 crore
NTPC is likely to finalise the acquisition of entire stake of Bihar State Power Holding Company Ltd (BSPHC) in its two JV plants at Nabinagar and Kanti for around Rs3,000 crore in a month
New Delhi: State-run power giant NTPC is likely to finalise the acquisition of entire stake of Bihar State Power Holding Company Ltd (BSPHC) in its two JV plants at Nabinagar and Kanti for around Rs3,000 crore in a month.
“The negotiation is in advance stages. NTPC will acquire entire stake of BSPHC, erstwhile Bihar State Electricity Board (BSEB), in Kanti and Nabinagar plants for around Rs3,000 crore in a month,” a source said. Earlier the Bihar political leadership has spoken many times about their intend to sell the BSPHC stake in the Nabinagar and Kanti power plants to NTPC.
Kanti Bijlee Utpadan Nigam, (formerly known as Vaishali Power Generating Company Ltd) was incorporated on 6 September, 2006, with NTPC contributing 51% of equity. The BSEB has the remaining equity in the joint venture which was renamed as Kanti Bijlee Utpadan Nigam on 10 April, 2008. Present equity holding of NTPC is 64.57% & BSEB is 35.43%.
It has 610 MW installed power generation capacity. Similarly, Nabinagar project known as Nabinagar Power Generation Company Pvt Ltd is also a joint venture of the NTPC and BSEB. The equity participation of the NTPC and BSEB is 50:50. The plant has 500 MW installed generation capacity and another 500 MW is under construction.
Apart from Bihar, the company is also eyeing stakes in other stressed assets and plants owned by the state utilities. The company is also looking at power generation units owned by Rajasthan utilities, the source said, adding that a deal could materialise in the next financial year.
Editor's Picks »
- RIL Q3 results: Will Reliance Jio, Reliance Retail make up for lost energy?
- Why Tata Motors’ Project Charge at JLR is failing to recharge its shares
- Outlook on global profit growth worst since 2008 financial crisis
- Q3 results: ICICI Securities loses its retail broking crown
- High drug approvals to keep up pricing pressure for pharma firms